AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NVCR · NASDAQ · Medical - Devices

Novocure (NVCR)

Develops wearable TTFields devices for brain, thoracic and pancreatic tumors.

$16.00

vs last close−0.67 (−4.00%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	127	134	139	150	155	161	155	159	167	174	174	184
Cost of revenue	32	33	34	35	35	33	39	41	45	42	39	41
Gross profit	95	101	105	116	120	128	116	117	122	132	135	142
	153	153	146	149	152	191	154	157	158	173	203	153
Research & development	54	54	52	55	52	51	54	56	54	61	58	51
	100	99	95	94	100	140	101	101	104	112	144	102
Selling & marketing	58	59	55	57	60	67	56	57	59	69	58	62
General & administrative	42	39	40	38	40	72	45	44	46	43	86	40
Operating income	−58	−52	−42	−34	−32	−63	−38	−40	−36	−40	−67	−11
	10	13	10	11	11	8	8	5	6	−1	−2	−2
Interest income	10	13	10	11	11	8	8	5	6	0	0	0
Interest expense	0	0	0	0	0	0	0	0	0	1	2	0
Other non-operating income	0	−13	−10	−11	−11	−50	−8	−5	−6	1	0	0
Income before tax	−48	−39	−32	−23	−22	−55	−30	−35	−30	−41	−69	−12
Income tax expense	1	9	7	11	9	11	4	5	7	−16	2	3
Net income from continuing operations	−49	−47	−39	−33	−31	−66	−34	−40	−37	−24	−71	−16
Net income	−49	−47	−39	−33	−31	−66	−34	−40	−37	−24	−71	−16
EPS, basic	−$0.46	−$0.44	−$0.36	−$0.31	−$0.28	−$0.61	−$0.31	−$0.36	−$0.33	−$0.22	−$0.62	−$0.13
EPS, diluted	−$0.46	−$0.44	−$0.36	−$0.31	−$0.28	−$0.61	−$0.31	−$0.36	−$0.33	−$0.22	−$0.62	−$0.13
Weighted average shares, basic	107	107	107	108	108	108	110	112	112	111	114	116
Weighted average shares, diluted	107	107	107	108	108	108	110	112	112	111	114	116
EBITDA	−55	−36	−29	−20	−19	−11	−27	−32	−26	−34	−63	−11
Depreciation & amortization	3	3	3	3	2	3	3	3	4	7	4	0
EBIT	−58	−39	−32	−23	−22	−14	−30	−35	−30	−41	−67	−11